Study to Improve Renal Function After Kidney Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2016-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to evaluate the safety and activity of a investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms of significant renal injury and are at risk for dialysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on Delayed Graft Function Using Paired Kidneys

NCT01561599

Delayed Graft Function

UNKNOWN PHASE2

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

NCT02474667

Delayed Graft Function

UNKNOWN PHASE3

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096

Delayed Graft Function

ACTIVE_NOT_RECRUITING PHASE2

A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Third Parties

NCT00980317

Kidney Neoplasms Renal Insufficiency Renal Replacement Therapy

UNKNOWN NA

Study of an Autologous Neo-Kidney Augment in Patients With Chronic Kidney Disease

NCT01846715

Chronic Kidney Disease

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Delayed graft function (DGF) is generally defined as the need for dialysis during the first 7 days after transplantation although the definition can also include failure to improve preexisting renal function. DGF is an important problem in renal allograft transplantation that affects approximately 25% of transplanted cadaveric kidneys. It has generally been observed that delayed graft function has been associated with reduced graft survival. In addition to an association of DGF with graft loss, DGF imposes an economic burden due to prolonged hospitalization and dialysis. The strongest association with occurrence of DGF is ischemia around the time of transplantation. Aside from approaches to minimize ischemia time and use of antibody induction, there are no good specific therapeutic options to prevent or treat delayed graft function. This study is designed to evaluate the safety and activity of an investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms of significant renal injury and are at risk for dialysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delayed Graft Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Saline

Placebo

Group Type PLACEBO_COMPARATOR

No interventions assigned to this group

BB3

Group Type ACTIVE_COMPARATOR

BB3

Intervention Type DRUG

intravenous drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BB3

intravenous drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females ≥ 18 years of age
2. Had renal transplantation due to end stage disease requiring chronic dialysis
3. Study drug can be administered within 36 hours after transplantation
4. Received kidney from healthy donor or donor with history of diabetes mellitus or hypertension
5. Donor terminal serum creatinine ≤ 2.2 mg/dL.
6. No urine output, OR average urine output of \< 50 cc/H over 8 or more consecutive hours, OR normal urine output following transplantation that diminished to average of \< 50 cc/H over 8 or more consecutive hours, OR creatinine reduction ratio at 24 hours after transplantation to pre-transplantation is \< 30%.
7. Reason for low urine output is unlikely due to structural changes. If clinically indicated, an ultrasound will be performed
8. Dry weight to\< 120kg and BMI \<35
9. Women of child bearing potential have a negative serum pregnancy test prior to transplantation.
10. Women of child bearing potential (including perimenopausal women who have had a menstrual period within 1 year) must agree to use 2 forms of effective birth control regimen (at least one-barrier method) during the 28-day study period. Men must agree to use condoms during the 28-day study period.
11. In the opinion of the investigator, the subject is capable of understanding and complying with the protocol.
12. Subjects must have signed the informed consent document prior to performance of any study related procedure including screening procedure.

Exclusion Criteria

1. Subject with normal urine output and not requiring dialysis prior to renal transplantation (i.e., had pre-emptive renal transplantation).
2. Signs and symptoms of volume depletion.
3. Recipient of multiple organ transplantation or scheduled for multiple organ transplantation.
4. Recipient of pediatric en-bloc kidney transplantation.
5. Recipient of kidney with cold ischemia time \> 40 hours
6. Has measurable donor-specific antibody or positive cross-match requiring deviation from standard immunosuppressive therapy.
7. Currently participating in or has participated in an investigational drug or medical device study within 30 days or five half-lives, whichever is longer, prior to enrollment into this study.
8. Concurrent sepsis or active bacterial infection.
9. Have an active malignancy or history of solid, metastatic or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed.
10. Women of child bearing potential who are breast feeding.
11. History of positive HIV test.
12. History of rheumatoid arthritis.
13. Subjects who require the cytochrome P450 1A2 (CYP1A2) inhibitors, ciprofloxacin and/or fluvoxamine (Luvox®)
14. Subject is unwilling or unable to comply with the protocol or to cooperate fully with the Investigator or the site personnel.
15. Subject is not deemed medically stable for the study in the opinion of the Investigator or the subject's primary nephrologist.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No